Evaluation of Risk Factors for Major Amputation in Patients With Diabetes and Peripheral Artery Disease Receiving Antiplatelet Therapy　― Post Hoc Analysis of a Prospective Observational Multicenter Cohort Study (SEASON)

• Published in: Circulation Journal Vol. 83; no. 9; pp. 1929 - 1936
• Main Authors: Higashi, Yukihito, Miyata, Tetsuro, Shigematsu, Hiroshi, Origasa, Hideki, Fujita, Masatoshi, Matsuo, Hiroshi, Naritomi, Hiroaki, Nakajima, Masahide, Yuki, Satoshi, Awano, Hideto
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Circulation Society 23.08.2019
• Subjects: Amputation; Ankle-brachial index; Diabetes; Japan; Peripheral arterial disease; Peripheral arterial disease; Diabetes; Ankle-brachial index; Japan; Amputation
• ISSN: 1346-9843; 1347-4820; 1347-4820
• DOI: 10.1253/circj.CJ-19-0088

Background:Guidelines for peripheral arterial disease (PAD) recommend long-term antiplatelet therapy in symptomatic patients to reduce cardiovascular morbidity and mortality risk. Although diabetes is a known risk factor for PAD, PAD has been undertreated in these patients. This study aimed to evaluate risk factors for major amputation in patients with diabetes undergoing antiplatelet therapy for PAD.Methods and Results:This retrospective analysis of a 2-year observational cohort study (1,745 clinics in Japan, September 2009–2013) evaluated predictors of amputation in patients with diabetes undergoing antiplatelet therapy for PAD. Among 4,016 eligible patients, 52 had an amputation during follow-up. Amputation risk (Cox regression analysis) was predicted at baseline by history of lower extremity revascularization/amputation (hazard ratio [HR]: 2.92; 95% confidence interval [CI]: 1.39, 6.14), chronic kidney disease (HR: 4.19; 95% CI: 1.95, 8.97), and comorbid cerebrovascular and heart disease (HR: 3.32; 95% CI: 1.19, 9.30), and was unaffected by choice of oral antiplatelet therapy. In patients with PAD and diabetes, amputation event rate was highest for those with ankle-brachial pressure index (ABI) <0.40 and progressively decreased at higher ABI cut-offs.Conclusions:These findings inform real-world understanding of PAD in diabetic patients receiving antiplatelet therapy in Japan, and showed that ABI <0.4 was the strongest risk factor for amputation.